Platelet-derived growth factors (PDGFs) are involved in various physiological and pathological processes, making them important targets for drug development. However, current methods for measuring PDGF bioactivity do not meet the rapidly growing requirements of pharmaceutical research. Here, we describe a novel reporter gene assay (RGA) for PDGF-BB activity measurement. RGA was developed with engineered cells expressing a modified luciferase protein under the control of an SRE element. With PDGF-BB stimulation, cells produced stable dose-dependent signals with a correlation coefficient of R² > 0.97 within several hours. The relative accuracy of the assay, represented by the relative bias for five independent samples with different bioactivity levels, was less than 4.67%. Variations in RGA caused by intra- and inter-assay factors were smaller than 10% and 15%, respectively. RGA not only yielded consistent results for estimating PDGF-BB activity, but also presented significantly lower variations than did the traditional colorimetric assay. Moreover, RGA could be completed within 2 days, showing a much higher efficiency than the WST method, which requires 4–5 days. Furthermore, RGA is suitable for other PDGF species besides PDGF-BB. Our results demonstrate that RGA could be a powerful tool for screening and identifying PDGF-related drug candidates in pharmaceutical applications.

血小板衍生生长因子（PDGF）参与各种生理和病理过程，使其成为药物开发的重要目标。但是，目前用于测量PDGF生物活性的方法不能满足药物研究迅速增长的要求。在这里，我们描述了一种用于PDGF-BB活性测定的新型报道基因测定法（RGA）。使用在SRE元件控制下表达修饰的萤光素酶蛋白的工程细胞开发了RGA。通过PDGF-BB刺激，细胞产生稳定的剂量依赖性信号，相关系数为R ² 在几个小时内> 0.97。用具有不同生物活性水平的五个独立样品的相对偏差表示的测定的相对准确度小于4.67％。由测定内和测定间因素引起的RGA差异分别小于10％和15％。RGA不仅获得了用于估计PDGF-BB活性的一致结果，而且与传统比色测定法相比，其变异性也大大降低。此外，RGA可以在2天内完成，显示出比WST方法（需要4-5天）更高的效率。此外，除了PDGF-BB，RGA还适用于其他PDGF种类。我们的结果表明，RGA可能是用于筛选和鉴定药物应用中与PDGF相关的候选药物的强大工具。